Publications by authors named "M Gil-Gil"

Claim this Profile
N
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.
Miguel Martín, Angel L Guerrero-Zotano, María E Pérez-López, Manuel Ruiz-Borrego, Noelia Martinez Jañez, Miguel Gil-Gil

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
E L Mayer, D Hlauschek, M Gnant, P J O'Brien, M Bellet-Ezquerra

Ann Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic and Predictive Impact of Circulating Tumour DNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.
Iseult M Browne, Javier Pascual, Rosalind J Cutts, Belinda Kingston, Sarah Hrebien, Miguel J Gil-Gil

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.
A Llombart-Cussac, J M Pérez-García, M Bellet, F Dalenc, M Gil-Gil

ESMO Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.
Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil, Christoph Zielinski, Manuel Ruiz-Borrego

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis